相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Thorsten Zenz et al.
BLOOD (2009)
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Davide Rossi et al.
CLINICAL CANCER RESEARCH (2009)
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine
Sona Cejkova et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
F. Dicker et al.
LEUKEMIA (2009)
A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
O. G. Best et al.
LEUKEMIA (2009)
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Chronic lymphocytic leukemia and treatment resistance in cancer The role of the p53 pathway
Thorsten Zenz et al.
CELL CYCLE (2008)
Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia
J. Malcikova et al.
MOLECULAR IMMUNOLOGY (2008)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast
D. Grochova et al.
ONCOGENE (2008)
Molecular basis of the Li-Fraumeni syndrome:: an update from the French LFS families
G. Bougeard et al.
JOURNAL OF MEDICAL GENETICS (2008)
Chronic lymphocytic leukemia
Paolo Ghia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Risk stratification in chronic lymphocytic leukemia
T Seiler et al.
SEMINARS IN ONCOLOGY (2006)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The P53 pathway: what questions remain to be explored?
A. J. Levine et al.
CELL DEATH AND DIFFERENTIATION (2006)
Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)
D Caballero et al.
CLINICAL CANCER RESEARCH (2005)
p53 mutation heterogeneity in cancer
T Soussi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
J Bartkova et al.
NATURE (2005)
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation
WJM Mackus et al.
LEUKEMIA (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
How many mutant p53 molecules are needed to inactivate a tetramer?
WM Chan et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations
RN Damle et al.
BLOOD (2004)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
GA Lang et al.
CELL (2004)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features
A Guarini et al.
BLOOD (2003)
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
I Sturm et al.
CELL DEATH AND DIFFERENTIATION (2003)
Genetics of chronic lymphocytic leukemia:: genomic aberrations and VH gene mutation status in pathogenesis and clinical course
S Stilgenbauer et al.
LEUKEMIA (2002)
Tumour p53 mutations exhibit promoter selective dominance over wild type p53
P Monti et al.
ONCOGENE (2002)
Cellular and clinical pharmacology of fludarabine
V Gandhi et al.
CLINICAL PHARMACOKINETICS (2002)
p53 dysfunction in B-cell chronic lymphocytic leukemia:: inactivation of ATM as an alternative to TP53 mutation
AR Pettitt et al.
BLOOD (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect
MV Blagosklonny
FASEB JOURNAL (2000)
High metastatic potential in mice inheriting a targeted p53 missense mutation
G Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
